Medpace, Eli Lilly and Company, and Thermo Fisher Scientific are the three Pharmaceutical stocks to watch today, according to MarketBeat's stock screener tool. Pharmaceutical stocks are shares of publicly traded companies that research, develop, manufacture, and market medications and related health products. Investors buy these equities to gain exposure to the biotech and drug-development sectors, hoping to profit from breakthroughs in treatments, patent protections, and global demand for healthcare solutions. These companies had the highest dollar trading volume of any Pharmaceutical stocks within the last several days.
Medpace (MEDP)
Medpace Holdings, Inc. engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.
Shares of NASDAQ MEDP traded up $172.09 during midday trading on Tuesday, hitting $480.97. The company's stock had a trading volume of 3,265,359 shares, compared to its average volume of 395,114. Medpace has a 1-year low of $250.05 and a 1-year high of $500.10. The firm's fifty day moving average price is $307.47 and its 200-day moving average price is $317.86. The firm has a market cap of $13.82 billion, a P/E ratio of 36.28, a P/E/G ratio of 5.64 and a beta of 1.47.
Read Our Latest Research Report on MEDP
Eli Lilly and Company (LLY)
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
Eli Lilly and Company stock traded up $11.67 during midday trading on Tuesday, reaching $773.85. 1,473,354 shares of the stock traded hands, compared to its average volume of 3,653,470. The company has a current ratio of 1.37, a quick ratio of 1.06 and a debt-to-equity ratio of 2.18. The firm has a fifty day moving average price of $767.03 and a two-hundred day moving average price of $800.17. The firm has a market cap of $733.41 billion, a price-to-earnings ratio of 62.95, a PEG ratio of 1.12 and a beta of 0.40. Eli Lilly and Company has a fifty-two week low of $677.09 and a fifty-two week high of $972.53.
Read Our Latest Research Report on LLY
Thermo Fisher Scientific (TMO)
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.
Shares of NYSE:TMO traded up $20.15 during trading on Tuesday, reaching $425.09. The company had a trading volume of 2,018,744 shares, compared to its average volume of 2,026,205. The firm's fifty day moving average is $410.38 and its 200 day moving average is $472.32. The firm has a market capitalization of $160.47 billion, a PE ratio of 24.93, a price-to-earnings-growth ratio of 2.21 and a beta of 0.77. Thermo Fisher Scientific has a twelve month low of $385.46 and a twelve month high of $627.88. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.38 and a current ratio of 1.77.
Read Our Latest Research Report on TMO
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Medpace, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Medpace wasn't on the list.
While Medpace currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
